Growth hormone
CJC-1295
A long-acting growth-hormone-releasing-hormone analogue studied mainly for hormone changes.
Human research / important limitations
Also known as: CJC1295
Practical use
Applying the explained evidence
- Where it fits
- A long-acting growth-hormone-releasing-hormone analogue studied mainly for hormone changes.
- Put the information into practice
- An increase in GH or IGF-1 is a biomarker change. It does not by itself establish improved recovery, muscle gains, longevity or safety.
- Outcome versus a marker
- Separate a change in a hormone measurement or body-composition estimate from the outcome you actually care about. Look for direct measurement of function, symptoms and adverse events.
- Keep this limit in view
- The outcomes were hormone concentrations and drug behavior, not long-term physique or health outcomes. Early tolerability does not negate later safety concerns.
Overview
CJC-1295 stimulates the growth-hormone axis. The cited trials studied a long-acting formulation; differently labeled products should not be assumed equivalent.
Risks and limitations
FDA reports limited clinical data and serious events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. Compounded peptides also raise impurity and immune-response concerns.
How to read this
An increase in GH or IGF-1 is a biomarker change. It does not by itself establish improved recovery, muscle gains, longevity or safety.
Research explained
Two early randomized trials
Who was studied
Healthy adults aged 21–61; study durations of 28 and 49 days.
What was found
GH and IGF-1 remained elevated for several days. No serious adverse reactions were reported in these trials.
What it cannot establish
The outcomes were hormone concentrations and drug behavior, not long-term physique or health outcomes. Early tolerability does not negate later safety concerns.
Read the original studyThe long-acting formulation is part of the result
The cited research tested a long-acting analog. Labels such as “with DAC” and “without DAC” should not be treated as interchangeable descriptions of that trial material. A formulation difference can change exposure substantially; the name alone is not enough to transfer its pharmacokinetic findings.
Supporting sourceBiomarkers are a starting point
A prolonged rise in GH or IGF-1 shows that an endocrine pathway responded. It does not measure tendon healing, useful strength, sleep quality or longer life. Those outcomes would require their own controlled studies.
Supporting sourceCommon questions
Why mention safety concerns when the early trial reported no serious reactions?
Small early studies can miss uncommon or delayed harms. FDA’s subsequent review identifies limited clinical data and serious associated events. Both belong in the explanation.
SourceSources
Sources checked 2026-09-28.
General education; not a personal treatment plan.